Chasing the KRAS field, Quanta Therapeutics bags $50M for two 2024 clinical trials
Quanta Therapeutics will bring its KRAS inhibitors into the clinic next year with a fresh heap of $50.7 million from blue-chip investors as it looks to catch up to the KRAS leaders and take the difficult class into other mutations and broader areas of oncology.
While two KRAS inhibitors are on the market, Amgen’s Lumakras and Mirati’s Krazati, researchers and drugmakers still see plenty of room for next-generation drugs with fewer liver toxicities, expansion into other mutations and avoidance of resistance to the inhibitors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
